Who owns Aktis Oncology, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of AKTS from SEC Form 13F filings across 125 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 125 institutions disclosed 36.8M shares of Aktis Oncology, Inc. worth $716.6M — about 66.1% of shares outstanding; the largest disclosed holder is MPM BIOIMPACT LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
125
13F holders
$716.6M
value, 2026 filers
66.1%
of shares outstanding (36.8M sh)
32
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of AKTS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | MPM BIOIMPACT LLC | 4.8M | $94.2M | 7.0% | 8.7% | 0.0% |
| 2 | EcoR1 Capital, LLC | 4.8M | $93.9M | 4.2% | 8.7% | 0.0% |
| 3 | Blue Owl Capital Holdings LP | 3.3M | $65.1M | 11.9% | 6% | +8.9% |
| 4 | T. Rowe Price Investment Management, Inc. | 3.3M | $64.9M | 0.0% | 6% | +62.5% |
| 5 | BlackRock, Inc. | 2.8M | $54.1M | 0.0% | 5% | +22.1% |
| 6 | RTW INVESTMENTS, LP | 1.6M | $31.0M | 0.3% | 2.9% | 0.0% |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 1.5M | $28.7M | 0.0% | 2.6% | -25.1% |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.2M | $23.1M | 0.0% | 2.1% | +55.2% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $23.0M | 0.0% | 2.1% | +44.5% |
| 10 | EVENTIDE ASSET MANAGEMENT, LLC | 1.1M | $20.7M | 0.3% | 1.9% | +110.1% |
| 11 | STATE STREET CORP | 1.1M | $20.5M | 0.0% | 1.9% | +117.0% |
| 12 | BAKER BROS. ADVISORS LP | 996,351 | $19.4M | 0.1% | 1.8% | 0.0% |
| 13 | Merck & Co., Inc. | 952,844 | $18.6M | 2.3% | 1.7% | 0.0% |
| 14 | ArrowMark Colorado Holdings LLC | 852,159 | $16.6M | 0.8% | 1.5% | +246.6% |
| 15 | Octagon Capital Advisors LP | 713,000 | $13.9M | 1.8% | 1.3% | -25.8% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 690,427 | $13.4M | 0.0% | 1.2% | +32.6% |
| 17 | Avidity Partners Management LP | 484,200 | $9.4M | 1.9% | 0.9% | 0.0% |
| 18 | TWO SIGMA INVESTMENTS, LP | 436,467 | $8.5M | 0.0% | 0.8% | +1311.9% |
| 19 | a16z Capital Management, L.L.C. | 415,000 | $8.1M | 0.0% | 0.7% | 0.0% |
| 20 | Affinity Asset Advisors, LLCNEW | 350,000 | $6.8M | 0.3% | 0.6% | new |
| 21 | Alyeska Investment Group, L.P. | 290,000 | $5.6M | 0.0% | 0.5% | 0.0% |
| 22 | NORTHERN TRUST CORP | 236,638 | $4.6M | 0.0% | 0.4% | +31.0% |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 230,818 | $4.5M | 0.0% | 0.4% | +38.3% |
| 24 | TD ASSET MANAGEMENT INC | 203,494 | $4.0M | 0.0% | 0.4% | +92.2% |
| 25 | VANGUARD PORTFOLIO MANAGEMENT LLC | 198,386 | $3.9M | 0.0% | 0.4% | +36.6% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.